AI drug design startup Chai Discovery raised $400M led by Index at a $3.8B valuation, as it positions its Chai models as AI infrastructure for pharmaceuticals (Michael J. de la Merced/New York Times)

<a href="https://www.nytimes.com/2026/07/14/business/dealbook/chai-discovery-ai-drug-development.html"><img align="RIGHT" border="0" hspace="4" src="http://www.techmeme.com/260714/i14.jpg" vspace="4" /></a> <p><a href="https://www.techmeme.com/260714/p14#a260714p14" title="Techmeme permalink"><img height="12" src="http://www.techmeme.com/img/pml.png" style="border: none; padding: 0; margin: 0;" width="11" /></a> Michael J. de la Merced / <a href="https://www.nytimes.com/">New York Times</a>:<br /> <span style="font-size: 1.3em;"><b><a href="https://www.nytimes.com/2026/07/14/business/dealbook/chai-discovery-ai-drug-development.html">AI drug design startup Chai Discovery raised $400M led by Index at a $3.8B valuation, as it positions its Chai models as AI infrastructure for pharmaceuticals</a></b></span>&nbsp; &mdash;&nbsp; The fund-raising values the company at $3.8 billion and underscores investor interest in using artificial intelligence to tackle problems like drug discovery.</p>